We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.96%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.07B
AUM Growth
+$361M
Cap. Flow
+$391M
Cap. Flow %
18.88%
Top 10 Hldgs %
46.93%
Holding
58
New
10
Increased
9
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$105M
2
GILD icon
Gilead Sciences
GILD
+$66.6M
3
CI icon
Cigna
CI
+$66M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$64M
5
PRGO icon
Perrigo
PRGO
+$59M

Top Sells

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$68.8M
2
ABBV icon
AbbVie
ABBV
+$51.4M
3
DGX icon
Quest Diagnostics
DGX
+$42.9M
4
MASI
Masimo
MASI
+$41.8M
5
NUVA
NuVasive, Inc.
NUVA
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 64.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$209M 10.12%
+1,000,000
New +$207M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$40.5B
$144M 6.97%
2,870,000
+620,000
+28% +$33M
VTRS icon
3
Viatris
VTRS
$20.4B
$118M 5.73%
2,740,000
+890,000
+48% +$39.4M
GILD icon
4
CALL
Gilead Sciences
GILD
$161B
$83.4M 4.03%
1,000,000
+500,000
+100% +$44.4M
ENDP
5
DELISTED
Endo International plc
ENDP
$78.7M 3.8%
+5,045,000
New +$105M
CSII
6
DELISTED
Cardiovascular Systems, Inc.
CSII
$75.3M 3.64%
+4,100,000
New +$64M
MDCO
7
DELISTED
Medicines Co
MDCO
$67.3M 3.25%
2,000,000
-500,000
-20% -$17.6M
BIIB icon
8
Biogen
BIIB
$30B
$66.5M 3.21%
275,000
+100,000
+57% +$26.4M
CI icon
9
Cigna
CI
$74.6B
$64M 3.09%
+500,000
New +$66M
GHDX
10
DELISTED
Genomic Health, Inc.
GHDX
$63.7M 3.08%
2,458,100
– –
OFIX icon
11
Orthofix Medical
OFIX
$466M
$63.6M 3.07%
1,500,000
– –
GILD icon
12
Gilead Sciences
GILD
$161B
$62.6M 3.02%
+750,000
New +$66.6M
BKD icon
13
Brookdale Senior Living
BKD
$3.47B
$61.8M 2.98%
4,000,000
-1,000,000
-20% -$17.4M
SEM
14
DELISTED
Select Medical
SEM
$60.6M 2.93%
10,347,200
– –
NKTR icon
15
Nektar Therapeutics
NKTR
$2.39B
$60.5M 2.92%
283,333
-16,667
-6% -$3.73M
LIVN icon
16
LivaNova
LIVN
$4.4B
$60.3M 2.91%
1,200,000
– –
TEVA icon
17
CALL
Teva Pharmaceuticals
TEVA
$40.5B
$56.5M 2.73%
1,125,000
+125,000
+13% +$6.65M
PRGO icon
18
Perrigo
PRGO
$1.4B
$51.7M 2.5%
+570,000
New +$59M
LDRH
19
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$50.8M 2.46%
1,375,000
-875,000
-39% -$24.8M
COR icon
20
Cencora
COR
$60.3B
$49.6M 2.4%
+625,000
New +$50.1M
NUVA
21
DELISTED
NuVasive, Inc.
NUVA
$44.8M 2.16%
750,000
-750,000
-50% -$40.5M
UAM
22
DELISTED
Universal American Corp
UAM
$44.5M 2.15%
5,875,000
– –
WMGI
23
DELISTED
Wright Medical Group Inc
WMGI
$43M 2.08%
2,475,000
+1,022,400
+70% +$18.8M
CYH icon
24
Community Health Systems
CYH
$385M
$41.6M 2.01%
+3,450,000
New +$50.5M
ALKS icon
25
Alkermes
ALKS
$8.21B
$40.5M 1.96%
937,300
-262,700
-22% -$10.8M
1
2 3

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Camber Capital Management held 58 positions worth $2.07B, up 21% from $1.71B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Camber Capital Management deployed $391M of net new capital in Q2 2016, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Endo International plc: 5,045,000 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 69% a quarter earlier.

On the sell side, the largest reduction was NuVasive, Inc., an estimated $40.5M trimmed.

  • Camber Capital Management's largest Q2 2016 buy was Endo International plc: 5,045,000 shares worth $78.7M.
  • Camber Capital Management added most to Viatris in Q2 2016, an estimated $39.4M increase.
  • Camber Capital Management's biggest Q2 2016 reduction was NuVasive, Inc., cutting an estimated $40.5M.
  • Camber Capital Management fully exited St Jude Medical in Q2 2016, selling an estimated $68.8M.
  • Camber Capital Management's ten largest holdings make up 47% of its $2.07B portfolio in Q2 2016.
  • Camber Capital Management opened 10 new positions and closed 10 in Q2 2016.
  • Camber Capital Management's portfolio value rose 21% quarter-over-quarter to $2.07B.

Based on Camber Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.